Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post CD19-CAR-T: an EPICOVIDEHA survey
Patients with previous CD19 directed chimeric antigen receptor T cell therapy (CAR T)-cell therapy have a prolonged vulnerability to viral infections. Coronavirus diseases 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real wor...
Saved in:
| Published in: | Blood advances |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
by The American Society of Hematology
18-04-2023
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Patients with previous CD19 directed chimeric antigen receptor T cell therapy (CAR T)-cell therapy have a prolonged vulnerability to viral infections. Coronavirus diseases 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real world data of the impact of vaccination and treatment on patients with COVID-19 after CD19 directed CAR T-cell therapy are lacking. Therefore, this multicenter retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the
Omicron
variant had a significantly lower risk of death due to COVID-19 compared to patients infected with previous variants (7% versus 58% (P=0.012)). Twenty-six patients were vaccinated at time of COVID-19 diagnosis. Two vaccinations showed marked but unsignificant reduction risk of COVID-19 caused mortality (33.3% versus 14.2% (P=0.379)).Also the course of disease appears milder with less frequent ICU admissions (39% versus 14% (P=0.054)) and shorter duration of hospitalization (7 versus 27.5 days (P=0.022)). Of the available treatment options, only monoclonal antibodies seemed to be effectively reducing mortality from 32% to zero (P=0.036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. |
|---|---|
| AbstractList | Patients with previous CD19 directed chimeric antigen receptor T cell therapy (CAR T)-cell therapy have a prolonged vulnerability to viral infections. Coronavirus diseases 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real world data of the impact of vaccination and treatment on patients with COVID-19 after CD19 directed CAR T-cell therapy are lacking. Therefore, this multicenter retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the
Omicron
variant had a significantly lower risk of death due to COVID-19 compared to patients infected with previous variants (7% versus 58% (P=0.012)). Twenty-six patients were vaccinated at time of COVID-19 diagnosis. Two vaccinations showed marked but unsignificant reduction risk of COVID-19 caused mortality (33.3% versus 14.2% (P=0.379)).Also the course of disease appears milder with less frequent ICU admissions (39% versus 14% (P=0.054)) and shorter duration of hospitalization (7 versus 27.5 days (P=0.022)). Of the available treatment options, only monoclonal antibodies seemed to be effectively reducing mortality from 32% to zero (P=0.036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. |
| Author | BATINIĆ, Josip VAN DOESUM, Jaap A. ESPIGADO, Ildefonso VAN PRAET, Jens PETZER, Verena GARCÍA-SANZ, Ramón SALMANTON-GARCÍA, Jon DRGOŇA, Ľuboš CÓRDOBA-MASCUÑANO, Raul KULASEKARARAJ, Austin MAERTENS, Johan MARCHESI, Francesco GAVRIILAKI, Eleni VAN ANROOIJ, Bjorn FERNÁNDEZ, Noemí CABIRTA, Alba GOMES DA SILVA, Maria METAFUNI, Elisabetta RAMÓN-SÁNCHEZ, Cristina DE DRAGONETTI, Giulia CALBACHO, Maria DI BLASI, Roberta TISI, Maria Chiara NUNES RODRIGUES, Raquel GUIDETTI, Anna MARCHETTI, Monia TRAGIANNIDIS, Athanasios ORMAZABAL-VÉLEZ, Irati PAGANO, Livio CORNELY, Oliver A. LÓPEZ-GARCÍA, Alberto WOLF, Dominik JIMÉNEZ, Moraima HERNÁNDEZ-RIVAS, José-Ángel LAMURE, Sylvain FARINA, Francesca MARTÍN-GONZÁLEZ, Juan-Alberto MACHADO, Marina WEINBERGEROVÁ, Barbora RAHIMLI, Laman GRÄFE, Stefanie K. MEERTEN, Tom VAN BESSON, Caroline PLANTEFEVE, Gaëtan ALMEIDA, Joyce MARQUES DE LIÉVIN, Raphaël FALCES-ROMERO, Iker SCHÖNLEIN, Martin NORDLANDER, Anna BLENNOW, Ola |
| Author_xml | – sequence: 1 givenname: Jaap A. surname: VAN DOESUM fullname: VAN DOESUM, Jaap A. organization: University Medical Center Groningen, Groningen, Netherlands – sequence: 2 givenname: Jon surname: SALMANTON-GARCÍA fullname: SALMANTON-GARCÍA, Jon organization: University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany, University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany, German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany – sequence: 3 givenname: Francesco surname: MARCHESI fullname: MARCHESI, Francesco organization: Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy – sequence: 4 givenname: Roberta surname: DI BLASI fullname: DI BLASI, Roberta organization: Service d’Hematologie-Oncologie, Hopital St Louis, Assistance Publique - Hopitaux de Paris; Universite de Paris Diderot, Paris, France – sequence: 5 givenname: Iker surname: FALCES-ROMERO fullname: FALCES-ROMERO, Iker organization: La Paz University Hospital, Madrid, Spain, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain – sequence: 6 givenname: Alba surname: CABIRTA fullname: CABIRTA, Alba organization: Department of Hematology, Vall d’Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain – sequence: 7 givenname: Francesca surname: FARINA fullname: FARINA, Francesca organization: IRCCS Ospedale San Raffaele, Milan, Italy – sequence: 8 givenname: Caroline surname: BESSON fullname: BESSON, Caroline organization: Centre Hospitalier de Versailles, Le Chesnay, France; Université Paris-Saclay, UVSQ, Inserm, Équipe "Exposome et Hérédité", CESP, Villejuif, France – sequence: 9 givenname: Barbora surname: WEINBERGEROVÁ fullname: WEINBERGEROVÁ, Barbora organization: Department of Internal Medicine - Hematology and Oncology, Masaryk University Hospital Brno, Brno, Czech Republic – sequence: 10 givenname: Jens surname: VAN PRAET fullname: VAN PRAET, Jens organization: Department of Nephrology and Infectious diseases, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium – sequence: 11 givenname: Martin surname: SCHÖNLEIN fullname: SCHÖNLEIN, Martin organization: Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany – sequence: 12 givenname: Alberto surname: LÓPEZ-GARCÍA fullname: LÓPEZ-GARCÍA, Alberto organization: Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain – sequence: 13 givenname: Sylvain surname: LAMURE fullname: LAMURE, Sylvain organization: Department of Clinical Hematology, Montpellier University Hospital, IGMM UMR5535 CNRS, University of Montpellier, Montpellier, France – sequence: 14 givenname: Anna surname: GUIDETTI fullname: GUIDETTI, Anna organization: University of Milan and Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy – sequence: 15 givenname: Cristina DE surname: RAMÓN-SÁNCHEZ fullname: RAMÓN-SÁNCHEZ, Cristina DE organization: Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain, IBSAL, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain – sequence: 16 givenname: Josip surname: BATINIĆ fullname: BATINIĆ, Josip organization: University Hospital Centre Zagreb, Zagreb, Croatia; School of Medicine University of Zagreb, Zagreb, Croatia – sequence: 17 givenname: Eleni surname: GAVRIILAKI fullname: GAVRIILAKI, Eleni organization: Aristotle University of Thessaloniki, Thessaloniki, Greece – sequence: 18 givenname: Athanasios surname: TRAGIANNIDIS fullname: TRAGIANNIDIS, Athanasios organization: Aristotle University of Thessaloniki, Thessaloniki, Greece – sequence: 19 givenname: Maria Chiara surname: TISI fullname: TISI, Maria Chiara organization: Ospedale San Bortolo, Vicenza, Italy – sequence: 20 givenname: Gaëtan surname: PLANTEFEVE fullname: PLANTEFEVE, Gaëtan organization: Centre Hospitalier d'Argenteuil, Argenteuil, France – sequence: 21 givenname: Verena surname: PETZER fullname: PETZER, Verena organization: Department of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria – sequence: 22 givenname: Irati surname: ORMAZABAL-VÉLEZ fullname: ORMAZABAL-VÉLEZ, Irati organization: Complejo Hospitalario de Navarra, Iruña-Pamplona, Spain – sequence: 23 givenname: Joyce MARQUES DE surname: ALMEIDA fullname: ALMEIDA, Joyce MARQUES DE organization: Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland – sequence: 24 givenname: Monia surname: MARCHETTI fullname: MARCHETTI, Monia organization: Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy – sequence: 25 givenname: Johan surname: MAERTENS fullname: MAERTENS, Johan organization: Department of Microbiology, Immunology, and Transplantation, KULeuven, Leuven and Department of Hematology, UZ Leuven, Leuven, Belgium – sequence: 26 givenname: Marina surname: MACHADO fullname: MACHADO, Marina organization: Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain – sequence: 27 givenname: Austin surname: KULASEKARARAJ fullname: KULASEKARARAJ, Austin organization: King's College Hospital, London, United Kingdom, King’s College London, London, United Kingdom – sequence: 28 givenname: José-Ángel surname: HERNÁNDEZ-RIVAS fullname: HERNÁNDEZ-RIVAS, José-Ángel organization: Hospital Universitario Infanta Leonor, Madrid, Spain – sequence: 29 givenname: Maria surname: GOMES DA SILVA fullname: GOMES DA SILVA, Maria organization: Portuguese Institute of Oncology, Lisbon, Portugal – sequence: 30 givenname: Noemí surname: FERNÁNDEZ fullname: FERNÁNDEZ, Noemí organization: Hospital Universitario Marqués de Valdecilla, Santander, Spain – sequence: 31 givenname: Ildefonso surname: ESPIGADO fullname: ESPIGADO, Ildefonso organization: Department of Hematology, University Hospital Virgen Macarena - University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS / CSIC), Universidad de Sevilla (Departamento de Medicina), Seville, Spain – sequence: 32 givenname: Ľuboš surname: DRGOŇA fullname: DRGOŇA, Ľuboš organization: Department of Oncohematology, Comenius University and National Cancer Institute, Bratislava, Slovakia – sequence: 33 givenname: Giulia surname: DRAGONETTI fullname: DRAGONETTI, Giulia organization: Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy – sequence: 34 givenname: Elisabetta surname: METAFUNI fullname: METAFUNI, Elisabetta organization: Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy – sequence: 35 givenname: Maria surname: CALBACHO fullname: CALBACHO, Maria organization: Hospital Universitario 12 de Octubre, Madrid, Spain – sequence: 36 givenname: Ola surname: BLENNOW fullname: BLENNOW, Ola organization: Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden – sequence: 37 givenname: Dominik surname: WOLF fullname: WOLF, Dominik organization: Department of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria – sequence: 38 givenname: Bjorn surname: VAN ANROOIJ fullname: VAN ANROOIJ, Bjorn organization: University Medical Center Groningen, Groningen, Netherlands – sequence: 39 givenname: Raquel surname: NUNES RODRIGUES fullname: NUNES RODRIGUES, Raquel organization: Portuguese Institute of Oncology, Lisbon, Portugal – sequence: 40 givenname: Anna surname: NORDLANDER fullname: NORDLANDER, Anna organization: Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden – sequence: 41 givenname: Juan-Alberto surname: MARTÍN-GONZÁLEZ fullname: MARTÍN-GONZÁLEZ, Juan-Alberto organization: Hospital Univesitario Virgen del Rocío, Seville, Spain – sequence: 42 givenname: Raphaël surname: LIÉVIN fullname: LIÉVIN, Raphaël organization: Service d’Hematologie-Oncologie, Hopital St Louis, Assistance Publique - Hopitaux de Paris; Universite de Paris Diderot, Paris, France – sequence: 43 givenname: Moraima surname: JIMÉNEZ fullname: JIMÉNEZ, Moraima organization: Department of Hematology, Vall d’Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain – sequence: 44 givenname: Stefanie K. surname: GRÄFE fullname: GRÄFE, Stefanie K. organization: Faculty of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany – sequence: 45 givenname: Ramón surname: GARCÍA-SANZ fullname: GARCÍA-SANZ, Ramón organization: Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain, IBSAL, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain – sequence: 46 givenname: Raul surname: CÓRDOBA-MASCUÑANO fullname: CÓRDOBA-MASCUÑANO, Raul organization: Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain – sequence: 47 givenname: Laman surname: RAHIMLI fullname: RAHIMLI, Laman organization: University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany, University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany, German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany – sequence: 48 givenname: Tom VAN surname: MEERTEN fullname: MEERTEN, Tom VAN organization: University Medical Center Groningen, Groningen, Netherlands – sequence: 49 givenname: Oliver A. surname: CORNELY fullname: CORNELY, Oliver A. organization: University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany, University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, GermanyUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany, University of Cologne, Faculty of Medicine and University Hospital Cologne, Center for Molecular Medicine Cologne (CMMC), Cologne, Germany, German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany – sequence: 50 givenname: Livio surname: PAGANO fullname: PAGANO, Livio organization: Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy |
| BookMark | eNqljNFKwzAYhYNMcOreIS-QmaSrXbyR0lXWK2Ubuy1_00wjaf7SpIW9vbuQgddene_wHc49mXn0hhAq-FKItXxqHGIL7QRem7CUXErOVZqtb8hcrrKEqTTJZleW6o4sQvjmnIvsOUmVnBNXdT3oSPFE9_luzwo8Mkkn0Np6iBY9Bd_SDj1qhx7cpUbbYGtNoBeJY9TYGdpjiLTYCMWKfMcOL5cZLT-q4v1YbcptTsM4TOb8SG5P4IJZ_OYDeX0rD8WW9WPTmVYbHwdwdT_YDoZzjWDrv8bbr_oTp1pwIaRaieT_Dz98ympS |
| ContentType | Journal Article |
| Copyright | 2023 by The American Society of Hematology. 2023 The American Society of Hematology |
| Copyright_xml | – notice: 2023 by The American Society of Hematology. 2023 The American Society of Hematology |
| DBID | 5PM |
| DOI | 10.1182/bloodadvances.2022009578 |
| DatabaseName | PubMed Central (Full Participant titles) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2473-9537 |
| GroupedDBID | .1- .FO 0R~ 0SF 53G 5PM AALRI AAXUO ADVLN AFCTW AFRHN AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ EBS FDB GROUPED_DOAJ HYE OK1 ROL RPM THE W2D Z5R |
| ID | FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_101129413 |
| IEDL.DBID | RPM |
| ISSN | 2473-9529 |
| IngestDate | Tue Sep 17 21:31:00 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-pubmedcentral_primary_oai_pubmedcentral_nih_gov_101129413 |
| Notes | contributed equally to this work |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112941/ |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10112941 |
| PublicationCentury | 2000 |
| PublicationDate | 20230418 |
| PublicationDateYYYYMMDD | 2023-04-18 |
| PublicationDate_xml | – month: 4 year: 2023 text: 20230418 day: 18 |
| PublicationDecade | 2020 |
| PublicationTitle | Blood advances |
| PublicationYear | 2023 |
| Publisher | by The American Society of Hematology |
| Publisher_xml | – name: by The American Society of Hematology |
| SSID | ssj0001763592 |
| Score | 4.537642 |
| Snippet | Patients with previous CD19 directed chimeric antigen receptor T cell therapy (CAR T)-cell therapy have a prolonged vulnerability to viral infections.... |
| SourceID | pubmedcentral |
| SourceType | Open Access Repository |
| SubjectTerms | Regular |
| Title | Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post CD19-CAR-T: an EPICOVIDEHA survey |
| URI | https://pubmed.ncbi.nlm.nih.gov/PMC10112941 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Na8IwFH9MT7uMjW3sw0kOu8au38kuo9SKHraJiuwmMU1ZQZuirbD_fkm0oFeP4SUkJA_yPn7v9wBeWShEQEKKM5v52KMpxYynBAepzamyd7lvKryH0_Drh_QTTZMTNLUwBrTPl3mvWK17Rf5rsJXlmlsNTswaf8ZKjdQ35dlWC1rKODzy0U1kRXOsmW7Ijhe6mPoObSA8xLEMHvyQX9d03Y5OD_i6y9opKPLolxlcw9XBPETR_hg3cCGKW1iNTCkjkhmaRpMpjuUcO2jHOM_3sTzEihQpfZJ8pQ1rNazypdT4QKSEsq6UWglUym2F4r5NcRxN8OxdTUPJeBR_z0f9ZBihbb3Zib87-Bgks3iIT865KPesFAvNE30qUddn-KKb63LvoV3IQjwAEh4nXLgZdbXLIjxGM_UqXKSZ8N03FjwCOXeXp_OXPsOl7uaukzU26UC72tTiBVrbtO4aX7lrHvofliy2xQ |
| link.rule.ids | 230,315,729,782,786,866,887,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Na8IwFA_THbbLPtjGvpfDrrH2O9lllFppmTpRkd0kpikr1Fa0FfbfL4kW9OoxvITkkRfykvd7vwfAO3U5d7BLUKJTG1kkJoiyGCMn1hkR_i6zVYZ3OHYHP7gTSJocp86FUaB9Nk9bebZo5emvwlYuF0yrcWLasO8LMxLXlKVrDXAqDmy7vfdKV38rkmVN1UM2LNdExDZIDeLBhqYQ4bsIuyTsNmSAwJZ11g5hkXv3TPfy2BVegYudZwm9rfwanPD8BmSRyoKERQLH3miM_GKKDLihjKXbb0BI8xgKUyxYJn1y0SzTeSGhhVAIi6oUFsnhsliX0O_oBPneCE0-RDcYDCP_exp1gtCD62q14X-34LMbTPwQHSg4W24JLWaSYvpQIvRSVNO1HuYdaOZFzu8B5BbDjJsJMeVrh1uUJGJDGY8Tbptt6jwAfOwsj8cPfQNn4aTfm_WiwdcTOJdF4WXMR8fPoFmuKv4CGuu4elV28g8OMct8 |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Na8IwFA_TwdhlH2xj38th11j7ZRMvo7QVyzYnKrKb1CRlhdoWbYX990uiBb26Y3gJySMv5CXv934PgNfI4byDHYJiPbKRRRhBEWUYdZhOifB3qa0yvPtjZ_CN_UDS5HTrXBgF2qfzpJWli1aW_ChsZbGgWo0T04afnjAjcU1ZulawWGuAY3Fo28bOS139r0imNVUT2bAcExHbIDWQBxuaQoVvo-yStNuQQQJb1lrbh0bu3DW98_-s8gKcbT1M6G76XIIjnl2BNFTZkDCP4dgdjZGXT5EB1xGlyeY7EEYZg8Ikc5pK31w0y2SeS4ghFMK8KoVlcljkqxJ6vk6Q547QpCu6wWAYel_T0A_6LlxVyzX_vQZvvWDi9dGekrNiQ2wxk1TT-xKhm6KcrnUxb0AzyzN-CyC3KKbcjIkpXz3cikgsNpZyFnPbbEedO4APneX-8KEv4GTo92Yf4eD9AZzK2vAy9KPjR9AslxV_Ao0Vq56VqfwBUIbN_A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+SARS-CoV-2+vaccination+and+monoclonal+antibodies+on+outcome+post+CD19-CAR-T%3A+an+EPICOVIDEHA+survey&rft.jtitle=Blood+advances&rft.au=VAN+DOESUM%2C+Jaap+A.&rft.au=SALMANTON-GARC%C3%8DA%2C+Jon&rft.au=MARCHESI%2C+Francesco&rft.au=DI+BLASI%2C+Roberta&rft.date=2023-04-18&rft.pub=by+The+American+Society+of+Hematology&rft.issn=2473-9529&rft.eissn=2473-9537&rft_id=info:doi/10.1182%2Fbloodadvances.2022009578&rft.externalDBID=PMC10112941 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2473-9529&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2473-9529&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2473-9529&client=summon |